ASX Announcement **19 November 2026**

BlinkLab Receives $1.22 Million R&D Tax Incentive Refund

Highlights

- **$1,219,737 R&D Tax Incentive refund received.** This non-dilutive funding comes on top of the $16.2 million cash balance reported at the end of the September 2026 quarter.
- **The refund relates to the completion of the U.S. pilot study, initiation of the U.S. 510(k) pivotal program, and Australian clinical research**, including the MAGNET study collaboration with Monash University.
- **BlinkLab is well funded through its key near-term milestones**: completion of the U.S. pivotal study and submission to the FDA, expected in Q1 2027.
- **FDA clearance would open the U.S. market**, where an estimated 1 in 31 children is diagnosed with autism and families can often wait more than a year for a specialist assessment.

BlinkLab Limited (ASX:BB1) ("BlinkLab" or the "Company") is pleased to announce that it has received $1,219,737 under the Australian Government's Research and Development (R&D) Tax Incentive program.

The refund relates to eligible R&D expenditure on the final stages of the Company's U.S. pilot study, the initiation of its U.S. pivotal study, and clinical research in Australia, including collaborative research with the MAGNET study at Monash University. Together these programs support the development, validation and clinical investigation of BlinkLab's smartphone-based neurobehavioural assessment for autism.

Strong Balance Sheet Heading into a Catalyst-Rich Period

This refund comes on top of the $16.2 million cash balance reported at the end of the September 2026 quarter. BlinkLab is well funded to complete its U.S. pivotal study and lodge its submission to the FDA, which is expected in Q1 2027. The Company believes these milestones will open the way to commercialisation in the United States.

Addressing a Large and Growing Unmet Need

Autism is one of the most common neurodevelopmental conditions in childhood. In the U.S., approximately 1 in 31 children[1] is now identified with autism, and families commonly face long waits

[1] https://www.cdc.gov/autism/data-research/index.html

for specialist assessment. Diagnosis often comes years after the first concerns are raised, which means children miss the window when early intervention could work best. BlinkLab's smartphone-based diagnostic aid is designed to help close that gap by giving clinicians objective, scalable and accessible data that can support earlier and faster diagnosis.

Use of Funds

The funds will support BlinkLab's ongoing research and development activities, including progressing the U.S. pivotal study and FDA submission, continuing clinical research and collaborations in Australia, and broader product and regulatory development programs.

This announcement has been authorised for release by the Board of BlinkLab Limited.

For further information please contact:

Dr Henk-Jan Boele
Managing Director & CEO
henkjan@blinklab.org
M: +31 (0) 611 132 247

Brian Leedman
Non-Executive Chairman
brian@blinklab.org
M: +61 (0) 412 281 780

About BlinkLab Limited
BlinkLab Limited was founded by neuroscientists at Princeton University and is developing a smartphone-based diagnostic platform for autism. Its most advanced product, BlinkLab Dx1, is an autism diagnostic aid for clinicians that leverages smartphones, artificial intelligence, and machine learning to capture objective, reflex-based measures, supporting earlier and more accurate autism identification. This enables timely intervention during critical periods of brain development. BlinkLab is led by an experienced management team and Board with deep expertise in digital healthcare, computer vision, and AI, supported by a Scientific Advisory Board of leading experts in autism and brain development.